What works for human papillomavirus vaccine introduction in low and middle-income countries?

Papillomavirus Res. 2017 Dec:4:22-25. doi: 10.1016/j.pvr.2017.06.003. Epub 2017 Jun 8.

Abstract

Since 2007, low and middle-income countries (LMICs) have gained experience delivering HPV vaccines through HPV vaccination pilots, demonstration projects and national programmes. This commentary summarises lessons from HPV vaccination experiences in 45 LMICs and what works for HPV vaccination introduction. Methods included a systematic literature review, unpublished document review, and key informant interviews. Data were extracted from 61 peer-reviewed articles, 11 conference abstracts, 188 technical reports, and 56 interviews, with quantitative data analysed descriptively and qualitative data analysed thematically. Key lessons are described under five themes of preparation, communications, delivery, coverage achievements, and sustainability. Lessons learnt were generally consistent across countries and projects and sufficient lessons have been learnt for countries to deliver HPV vaccine through phased national rollout rather than demonstration projects. However, challenges remain in securing the political will and financial resources necessary to implement successful national programmes.

Keywords: Cervical cancer prevention; Demonstration projects; Human papillomavirus; Low and middle-income countries; Vaccination.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Developing Countries*
  • Female
  • Humans
  • Immunization Programs / economics
  • Immunization Programs / legislation & jurisprudence
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Infections / virology
  • Papillomavirus Vaccines / administration & dosage*
  • Papillomavirus Vaccines / economics
  • Poverty
  • Uterine Cervical Neoplasms / prevention & control*
  • Uterine Cervical Neoplasms / virology
  • Vaccination / adverse effects
  • Vaccination / economics*
  • Vaccination / legislation & jurisprudence

Substances

  • Papillomavirus Vaccines